





# Freeware Database for follow-up of HIV-patients and programs In

Infectious Diseases Department of Sihanouk Hospital Center of HOPE

### Issue

- Scaling-up clinical HIV care and treatment services
- This requires monitoring of individual patients, cohorts and evaluation programs
- This is a complex task
- Successfully performed: using an electronic database


## Patient monitoring

### 2 main functions:

 Enables effective clinical management of patients

 Patient monitoring data are used for program monitoring and management

### **Data-collection in SHCH**



027	2002000	vazoopiidii Gerger Ojazoaa																							Z/Ler Le	POSSED	er Or ror	100112	
										D.	ATA	COLI	LECT	NOL	SHE	ET 1													
Na	me:		RT	<u>у</u> Соф	e:	_ Ho	spitalı	numbe	r			Sex: 🗆	мП	Birth	Date:	Date: / /19 Date inclusion HIV				HIV D	IV Dot.: _// Place test: ☐ :HCH ☐ VCI ☐ Otto				] Offer				
																				rant 11=taxi/m <sub>0000</sub> /cyclo driver 12=CO/NGO 13=Other									
ΟÎ	man.	Penh. House #St	San	ebat_			Kh	an				. 01	rovince			Bloom		c	commun	ıe		Group .			Ni	strict_			
Tal	Ma	Contactness									ADTE	naria c	П	7 <sub>66</sub> П	No No	4 A DT	mmhar					DTSC.	do erre	****	de cer				
337	100 eta	re on envollment: 1 2 3 4	Wealth	ar Milosiach			lear I	anash		***	Ratio	v ∏ C	e. ⊔ Johal Do	res L nod 1	110 IN	Global	Emd 2	· —	Global	End /	1 1	nave. Toeva	лаечали Тот	nuchar	Dice. Di∩tha	· ·			
JJJJ.	*748**	EC. VII. CHILVIIII CHILI. I., A. J. J.		8.38.59.69	<b></b>	***********		æne ur	·····	<i>.</i>	A3003000	i <del></del>	#000###D	****		Nat ART number:   □ Global Fimd 2 □ Global Fimd 4			Tb	A.K.R.KK	<del>40.4</del>		X##5	<del></del>		***************************************	·······i		
PH		Date																											
		Place of consultation (CRC, ER)																											
		Pregnancy (Y or N)																								igsquare			
		Result (H, T, R, A)																											
		PCP prophylaxis (Y, N)																								igsquare			
		Fluco prophylaxis (Y, N)																											
		Weight (kg)																								igspace			
		Performance (W, A, B)																										igsquare	
888		BloodPressure																										igspace	
<u> </u>		Hemoglobin (g/dl)																										igsquare	
ᆜ		Total lymphocyte count (/mm²)																										igspace	
		CD4 (/mm²)																											
	1	Asymptomatic																											
		Minor skin/mouth problems																										igspace	
	2B	PPE																										igsquare	
		Episode repeated URTI																										igspace	
×5Y	7 20	H. Zoster																										igspace	
	2 E	Weight loss < 10% Weight loss > or = 10% Diarrhea > 1 month Oral candidias is Fever > 1 month Oral hairy leuhoplakia PTB sputum negative																										igspace	
	3A	Weight loss > or = 10%																											
	3B	Diamhea > 1 month																											
	3C	Oral candidiasis																											
	3D	Fever > 1 month																											
	3 E	Oral hairy <u>leukoplakia</u>																											
*17	3F	PTB sputum negative																											
	35	PIR shimm bositine																											
		Chronic vulyayagin, Cand.																											
		Severe bact, Infections																											
╧		Wasting syndrome																										igspace	
		PCP																										igspace	<u> </u>
	4C	Cerebral Toxoplasmosis																										igspace	
_		Cryptococcalmeninghis																										igspace	<u> </u>
1		HSV persistent or recurrent																										igsquare	<u> </u>
	4F	Cryptosporid, Diarth, > 1m																										igsquare	
$\bot$		Isospora diamhea > 1 m.																										igspace	
╙		CMV																										$\square$	
		Encephalopathy/Dementia																										$\square$	
╙		Disseminated mycosis																										igsquare	
4	+1	Esophag, Candid.																										igspace	
	+L	Non-typh Salmonella septicemia		I 1				I	I	I		I	I			I	I	I -	I	I -			I		I			i 7	

### **Database**

MS Access2003


C:\ArtJournal – v2

User manual

### In the database




### The data-entry tool



### The data-entry tool



### Patient follow-up



## Patient report

#### Patient report

ID:	37	Gender: M
Initials:	DS	Date HIV diagnosis
Birthday:	16-feb-75	Date enrolment: 30-jun-99
Age:	31	Reason drop-out:
		Date drop-out:

#### WHO stage defining conditions before enrolment

Start	Stop	Condition
Before enrolment	Before enrolment	Extrapulmonary tuberculosis
Before enrolment	Before enrolment	Oral candidiasis
Before enrolment	Before enrolment	Unexplained prolonged fever > 1 month

#### WHO stage at enrolment

WHO stage defining conditions after enrolment

Start	Stop	Condition	
04-jul-03	04-jul-03	Recurrent upper respiratory tract infections	
01-aug-03		VVeight loss <10%	
15-dec-03	19-ian-04	Recurrent upper respiratory tract infections	

#### WHO stage currently

#### Clinical parameters


Date	Weight	Performance
06-jun-03	50	
13-jun-03	51	
20-jun-03	51	
04-jul-03	51	

#### Laboratory results

Date	VL	Log VL	CD4	TLC	Hemoglobine	Creatinin	SGPT
20-jun-02			127				
06-jan-03			168				
11-jun-03			176				
29-jul-03					12		193
05-aug-03							115
13-aug-03					12,2		
28-okt-03					12,2		41
05-jan-04			286				33
09-apr-04					11,1		30
22-jun-04			369	2560			
04-okt-04					11,4		
05-nov-04					11,5		31

#### Last serology results

Test	Date	Result	
VDRL	22-jun-04	neg	



## Program report

#### Report HIV Treatment program

Generated by ArtJournal database

I. Overview patient population on: 31/08/2006

A. Total number of patients in active follow-up\*: 1538

\* Active follow-up means a patient had at least 1 visit in the last 6 months and is not known to be dead. transferred or lost-to-follow-up.

#### B. Patient characteristics:

#### Gender:

Gender	Number	%
F	835	54.3
M	703	45.7
Total	1538	

Age:

Average age: 36 years (Range: 0 -80)

#### C. Immunological data:

Number of patients with a CD4 count determined over the past 6 months: 1035. (=67.3% of the active patient population)

Number of patients with a TLC determined over the past 6 months: 1187. (=77.2% of the active patient population)

Last CD4 count in the active patient population:

Not on ART: Overall: On ART:

1 level	Number	%	CD4 level	Number	9
<200	411	26.7	<200	53	10.3
>=200	624	40.6	>=200	198	38.4
Not done	503	32.7	Not done	264	51.3

			_
Regimen	Num	nber	
lamivudine + nevirapine + stavudine		511	
efavirenz + lamivudine + stavudine		182	
lamivudine + nevirapine + zidovudine		176	
efavirenz + lamivudine + zidovudine		93	
abacavir + lamivudine + nevirapine		15	
abacavir + efavirenz + lamivudine		8	
lamivudine + lopinavir + stavudine		7	
abacavir + didanosine + lopinavir		5	
lamivudine + lopinavir + tenofovir		4	
lamivudine + lopinavir + zidovudine		3	
lamivudine + nevirapine + tenofovir		3	
abacavir + didanosine + lopinavir + ritonavir		2	
abacavir + indinavir + lamivudine + ritonavir		2	
abacavir + lamivudine + lopinavir		2	
·		2	
didanosine + indinavir + ritonavir + stavudine		_	
lamivudine + lopinavir + ritonavir + zidovudine		2	
efavirenz + indinavir + ritonavir		1	
abacavir + lamivudine + nevirapine + zidovudine		1	
Stage defining condition	Number	%*	
Weight loss >=10%	33	48.5	
Weight loss <10%	26	38.2	
Oral candidiasis	16	23.5	
Other Disease	14	20.6	
Diarrhoea>1 month	10	14.7	
Fever> 1 month	9	13.2	
Severe bact. Infections	9	13.2	
Minor skin/mouth problems	7	10.3	
	_		
PPE	6	8.8	
Abdominal LN TB	5	7.4	
Abdominal LN TB STI	5	7.4 5.9	
Abdominal LN TB STI PCP	5 4 2	7.4 5.9 2.9	
Abdominal LN TB STI PCP H. Zoster (in past 5 years)	5 4 2 2	7.4 5.9 2.9 2.9	
Abdominal LN TB STI PCP H. Zoster (in past 5 years) Esophag candid.	5 4 2 2 2	7.4 5.9 2.9 2.9 2.9	
Abdominal LN TB STI PCP H. Zoster (in past 5 years) Esophag candid. TB pleura-effusion	5 4 2 2 2 2	7.4 5.9 2.9 2.9 2.9 1.5	
Abdominal LN TB STI PCP H. Zoster (in past 5 years) Esophag candid. TB pleura-effusion PTB sputum negative	5 4 2 2 2 2 1 1	7.4 5.9 2.9 2.9 2.9 1.5	
Abdominal LN TB STI PCP H. Zoster (in past 5 years) Esophag candid. TB pleura-effusion PTB sputum negative Oral hairy leukoplakia	5 4 2 2 2 1 1 1	7.4 5.9 2.9 2.9 2.9 1.5 1.5	
Abdominal LN TB STI PCP H. Zoster (in past 5 years) Esophag candid. TB pleura-effusion PTB sputum negative Oral hairy leukoplakia PTB sputum positive	5 4 2 2 2 1 1 1 1	7.4 5.9 2.9 2.9 2.9 1.5 1.5	
Abdominal LN TB STI PCP H. Zoster (in past 5 years) Esophag candid. TB pleura-effusion PTB sputum negative Oral hairy leukoplakia PTB sputum positive Repeated URTI	5 4 2 2 2 1 1 1	7.4 5.9 2.9 2.9 2.9 1.5 1.5 1.5	
Abdominal LN TB STI PCP H. Zoster (in past 5 years) Esophag candid. TB pleura-effusion PTB sputum negative Oral hairy leukoplakia PTB sputum positive Repeated URTI Cryptococcal meningits	5 4 2 2 2 1 1 1 1 1	7.4 5.9 2.9 2.9 2.9 1.5 1.5	
Abdominal LN TB STI PCP H. Zoster (in past 5 years) Esophag candid. TB pleura-effusion PTB sputum negative Oral hairy leukoplakia PTB sputum positive Repeated URTI	5 4 2 2 2 1 1 1 1 1	7.4 5.9 2.9 2.9 2.9 1.5 1.5 1.5 1.5	

%\* 50.0 17.8 17.2 9.1

1.5

0.8 0.7

0.5 0.4

0.3

0.3 0.2

0.2

0.2 0.2 0.2 0.1 0.1

0.1

0.1

0.1 0.1

## Donor Report



### Sihanouk Hospital **Center of HOPE**



#### GF1 activity report

Reporting on cohort and opportunistic infections is only correct for GF1, GF2, GF4, not for Hospital+ITM

Some drop-out patients are only identified six months after their last contacts, so only reports made more than six months after the end of the reporting period are complete and final.

#### Reporting period

Reporting period: from	01/08/2006
till	31/08/2006

#### Cohort

Total patients	GF1	New patients
	419	
Reason of drop	out	Number of patients
Deceased		1

Number of patients ever on ART in this period	331
Number of patients started	87
Number of patients stopped	1
Number of patients on ART at the end of this period	330

Regimen	Number of patients
efavirenz/lamivudine/abacavir	3
efavirenz/stavudine/lamivudine	46
efavirenz/zidovudine/lamivudine	37
indinavir/ritonavir/lamivudine/abacavir	1
indinavir/ritonavir/stavudine/didanosine	2
indinavir/ritonavir/zidovudine/lamivudine	1
indinavir/stavudine/lamivudine	1
lopinavir/ritonavir/didanosine/abacavir	4
lopinavir/ritonavir/lamivudine/abacavir	1
lopinavir/ritonavir/lamivudine/tenofovir	2
lopinavir/ritonavir/stavudine/didanosine	1
lopinavir/ritonavir/stavudine/lamivudine	2
lopinavir/ritonavir/zidovudine/lamivudine	3
nevirapine/lamivudine/abacavir	3
nevirapine/lamivudine/tenofovir	2
nevirapine/stavudine/lamivudine	143
nevirapine/zidovudine/lamivudine	78

143

26

161 All treatment regimens reported are those at the end of the reporting period, in those on ART at that time

## **CCF** Report



#### Sihanouk Hospital Center of HOPE

The control of the co

Chronic care facility activity report

Funded through Global Fund Round 1 from 1-9-2003 till 31-8-2005

Nadir CD4	Number	Percent	
000-049	3	20	
050-199	6	40	
200-499	1	7	

#### Reporting period

Reporting period: from		01/08/2006	
1	till	31/08/2006	

#### Activity

Number of new admissions: 15
Total number of stays: 37

Total number of patients ever in the CCF during this period: 36

Total number of ends of CCF stays during this period: 12

Total patient-days of CCF stay during this period: 780

Average days for a CCF stay during this period: 21.081

#### Reasons for admission

Reason	Number	Percent
Convalescence	14	93
Missing	1	7

#### Outcome of CCF stay

Outcome	Number	Percent
Death	3	25
Discharge	7	58
Ran away	1	8
Referral to hospital	1	8

ART	Number	Percent
Not on ART	7	47
On ART	6	40
ART experience	2	13

### Duration of stay

Total days of stay	452
Average days of stay	37.6666666666667
Minimum days of stay	2
Maximum days of stay	134

## NCHADS Report

AZT+3TC+NVP

#### ម្រឹះវាទាំនភាមក្រក់ខ្លួន។ Kingdom of Cambodia ខាត់ សាសនា ក្រានមសារអូវគ្រ Nation Religion King

#### ៖ជាយការពត់ស្តីពីការព្យាជាលះជាយ ART (Facility ART Report)

ឈ្មោះអន្ទីពេឲ្យ Sihanou បង្អែក/ គ្គីនិក (Facility) Center	uk Hospital of HOPE	លេខកូដ (Facility code)	1	2	0	5
ឈ្មោះស្រុកប្រតិបត្តិ (Operational district)		ខេត្ត/ ក្រុង (Province) Phnom Penh				
ន្តាំ (Year) 2006		ត្រីមាសទី (Quarte	r) <b>2</b>			1/04/2006 0/06/2006
ប្រភេទ (Catego	ory)	អាយុ Age		សរុប Total		
ចំនួនអ្នកជំងឺ ដែលសកម្មខទូលបានព្យាបាល នៅចងត្រីមាសមុន	បដៅយ ART	> 14	402	407	809	)
[Number of active patients on ART at t quarter]	he end of preceding	0 - 14	0	1	1	
ចំនួនអ្នកជំងឺចាប់ផ្ដើមថ្មីព្យាបាលដោយ	ព្យាបាលដោយ ART > 14 <b>72 69</b>		141			
នៅក្នុងមន្ទីរពេឲ្យបង្អែក/គ្លីនិក នៅក្នុងគ្រីមាស		0 - 14	0	0	0	
[Number of new patients started in AR this facility during quarter this qua		សរុប Total	72	69	141	
ចំនួនអ្នកជំងឺដែលបានបញ្ជូនចូលក្នុងរយៈពេលមួយគ្រីមាស (Number of patients transferred in during quarter)		> 14	0	0	0	
		0 - 14	0	0	0	
		សរុប Total	0	0	0	
	បញ្ជូនចេញ	> 14	0	1	1	
	(Trånsfer out)	0 - 14	0	0	0	
ចំនួនអ្នកជំងឺដែលលះបង់ការព្យាបាល	លះចង់ការព្យាបាល	> 14	4	3	7	
ដោយ ART ក្នុងរយះពេលមួយត្រីមាស	(Lost)	0 - 14	0	0	0	
[Number of patients who left ART care	ស្លាប់ (Died)	> 14	5	4	9	
during quarter]	10 (	0 - 14	0	0	0	

រូបមន្ត ព្យាបាលសំរាប់មនុស្សពេញវ័យ Treatment regimen for Adult	ចំនួនអ្នកជំងឺ Number of patients	
d4T(30)+3TC+NVP	380	
d4T(40)+3TC+NVP	100	
AZT+3TC+NVP	130	
d4T(30)+3TC+EFV	142	
d4T(40)+3TC+EFV	32	
AZT+3TC+EFV	80	
ABC+3TC+NVP	13	
ABC+ddl(250)+Lop/Rit	6	
ABC+3TC+EFV	5	
AZT+3TC+Lop/Rit	3	
d4T(30)+3TC+Lop/Rit	3	
TDF+3TC+NVP	2	
d4T(30)+ddl(250)+Ind(400)/Rit	2	
ABC+3TC+Lop/Rit	2	
AZT+3TC+Ind/Rit	2	
d4T(30)+3TC+Ind(800)	1	
ABC+3TC+Ind(400)/Rit	1	
d4T(30)+ddl(250)+Lop/Rit	1	
d4T(40)+3TC+Lop/Rit	1	
EFV+Ind(800)/Rit	1	
Lop/Rit+ABC+ddl(400)	1	
TDF+3TC+Lop/Rit	1	
សរុប Total	909	
រូបមន្ត ព្យាបាល សំរាប់  កុមារ Treatment regimen for <i>Children</i>	ចំនួនអ្នកជំងឺ Number of patients	

## Monitoring

Data Monitoring

### Lessons learned

- An appropriate database greatly facilitates follow-up of individual patients and gives a better overview of program performance and outcomes
- The database facilitates the reporting required by different donors

### Recommendation

- http://telemedicine.itg.be/telemedicine/site/
   Default.asp
- Computer requirements: Window XP and MS Access 2003



# Thanks